HCPCS Level II drug code
J9041 — Injection, bortezomib, 0.1 mg
In short
J9041 is the HCPCS Level II code for injection, bortezomib, 0.1 mg. CMS assigns NDCs for Bortezomib and Velcade to it. One billing unit is 0.1 mg. The Medicare Part B payment limit is $2.628 per unit (October 1, 2026 through December 31, 2026).
Code
CMS HCPCS file- Descriptor
- Injection, bortezomib, 0.1 mg
- Short descriptor
- Injection, bortezomib, 0.1mg
- Code set
- HCPCS Level II, maintained by CMS
- Effective
- Jan 1, 2023
The billing unit is read from the descriptor. Confirm it against the CMS file before billing.
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Units and claim line
Units = dose given ÷ 0.1 mg. For example, 10 mg is 100 units. Enter the dose to get the units and the NDC line for the CMS-1500 and the 837P.
Enter the dose given to build the claim line.
NDCs billed under J9041
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 20 NDCs to J9041 for Bortezomib and Velcade. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Bortezomib | 00143-9098-01 | Hikma Pharmaceuticals USA Inc. | 1 | 35 |
| Bortezomib | 00409-1700-01 | Pfizer Inc | 1 | 35 |
| Bortezomib | 10019-0991-01 | Baxter Healthcare Corporation | 1 | 35 |
| Bortezomib | 25021-0244-10 | Sagent Pharmaceuticals | 1 | 35 |
| Bortezomib | 25021-0262-10 | Sagent Pharmaceuticals | 1 | 35 |
| Bortezomib | 43598-0426-60 | Dr. Reddy's Laboratories Inc. | 1 | 35 |
| Bortezomib | 50742-0484-01 | Ingenus Pharmaceuticals LLC | 1 | 35 |
| Bortezomib | 55150-0337-01 | Eugia US LLC | 1 | 35 |
| Bortezomib | 60505-6050-04 | Apotex Corp | 1 | 35 |
| Bortezomib | 63323-0821-10 | FreseniUS Kabi USA, LLC | 1 | 35 |
| Bortezomib | 68001-0534-36 | BluePoint Laboratories | 1 | 35 |
| Bortezomib | 68001-0540-36 | BluePoint Laboratories | 1 | 35 |
| Bortezomib | 68001-0541-36 | BluePoint Laboratories | 1 | 35 |
| Bortezomib | 70069-0836-01 | Somerset Pharma, LLC | 1 | 35 |
| Bortezomib | 70710-1411-01 | Zydus Pharmaceuticals (USA) Inc. | 1 | 35 |
| Bortezomib | 70860-0225-10 | Athenex Pharmaceutical Division, LLC | 1 | 35 |
| Bortezomib | 71288-0118-10 | Meitheal Pharmaceuticals Inc. | 1 | 35 |
| Bortezomib | 72205-0183-01 | Novadoz Pharmaceuticals LLC | 1 | 35 |
| Bortezomib | 72603-0270-01 | Northstar RxLLC | 1 | 35 |
| Velcade | 63020-0049-01 | Takeda Pharmaceuticals America, Inc. | 1 | 35 |
J9041: common questions
- Is J9041 a CPT code?
- No. J9041 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code. CPT codes for drug administration.
- What NDCs are billed under J9041?
- CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 20 NDCs under J9041, for Bortezomib and Velcade. The table on this page shows each one with its billing units per package.
- What is the Medicare payment limit for J9041?
- $2.628 per 0.1 mg, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.
- What is one billing unit of J9041?
- One unit of J9041 is 0.1 mg, as stated in the code's descriptor. Units to report = dose given ÷ 0.1 mg. J-code billing units.